Treatment effects of pulmonary artery denervation for pulmonary arterial hypertension stratified by REVEAL risk score: Results from PADN-CFDA trial
Section snippets
Study design and patient population
Patients eligible for PADN plus PDE-5i or sham PADN plus PDE-5i were randomized in a 1:1 ratio following right heart catheterization (RHC).16 Sample size calculation, randomization, and masking have been described previously.16 The study protocol was approved by the ethics committee of each participating site, and all patients or their legal representatives signed an informed consent form before enrolling in the trial. In addition, this study was registered at ClinicalTrials.gov (under the
Results
Among 128 PAH patients randomly assigned to PADN plus PDE-5i (n=63) or a sham procedure plus PDE-5i (n=65), 57 (44.5%) patients were at low risk and 71 (55.5%) were in the intermediate or high-risk groups (Supplemental Table 1 and Supplemental Figure 1). Patients in the intermediate- or high-risk group were generally characterized by 1) lower SBP, 2) frequent functional class III or IV, 3) common idiopathic PAH, 4) less 6 MWD, and 5) higher plasma concentration of NT-proBNP before
Discussion
PAH is an incurable chronic disease with high mortality resulting from progressive pulmonary arterial remodeling and subsequent RHF.17 The goal of PAH treatment is to achieve a low-risk status. Consequently, robust risk stratification is a key tool for guiding the treatment approach and predicting 1-year mortality.3, 4, 5, 6, 7, 8, 9, 10 One of these assessment tools, REVEAL Lite 2.010 involves six non-invasive parameters and is in good agreement with its previous versions. In this analysis
Authors contribution
Study design (Shao-Liang Chen, Gregg W. Stone, Xiaoyan Yan, Cheng Yao); patient enrollment (Juan Zhang, Caojin Zhang, Zhenwen Yang, Heping Gu, Fenling Fan, Hong Gu, Qiguang Wang, Dujiang Xie, Gangcheng Zhang, Xiaomei Guo, Yuehui Yin, Bowen Jin, Hongmei Zhou, Ziyang Yang, Zhouming Wang, Chen Zhang, Lili Meng, Xiaoyu Wang, Chunxia Zhao, Hang Zhang, Yu Xin); coordinator (Jing Kan); independent statisticians (Yongyue Wei, Feng Chen).
Disclosure statement
This trial was granted by the National Scientific Foundation of China (grant numbers: NSFC 91639303, NSFC 81770441, and NSFC 82121001). Nanjing First Hospital funded this trial, and Pulnovo provided all PADN catheters throughout the study period.
Dr. Stone has received speaker honoraria from Medtronic, Pulnovo, and Infraredx and has served as a consultant to Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Vectorious, Miracor, Neovasc, Abiomed, Ancora, Elucid Bio, Occlutech, CorFlow,
References (22)
- et al.
The REVEAL registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension
Chest
(2012) - et al.
Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC/ERS-Based risk assessment strategies
Chest
(2019) - et al.
Development and validation of an abridged version of the REVEAL 2.0 risk score calculator, REVEAL lite 2, for use in patients with pulmonary arterial hypertension
Chest
(2021) - et al.
Pulmonary artery denervation attenuates pulmonary arterial remodeling in dogs with pulmonary arterial hypertension induced by dehydrogenized monocrotaline
JACC Cardiovasc Interv
(2015) - et al.
Experimental pulmonary hypertension produced by surgical and chemical denervation of the pulmonary vasculature
Chest
(1980) - et al.
Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective, first-in-man PADN-1 study (first-in-man pulmonary artery denervation for treatment of pulmonary artery hypertension)
J Am Coll Cardiol
(2013) - et al.
Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology
J Am Coll Cardiol
(2013) - et al.
Diagnosis of pulmonary hypertension
Eur Respir J
(2019) - et al.
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Eur Respir J
(2022) - et al.
Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model
Eur Respir J
(2017)
A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension
Eur Heart J
Cited by (1)
- †
Contributed equally to the manuscript.